Yeah. Agree Ryan. Something doesn't stack up. The Phase 2b results were too far apart from the Phase 2a results. This should be explored by PER and explained to shareholders. One could reasonably expect perhaps a negative difference, but not such that the trial is terminated. To go from the stellar 2a results to what was found in the 2b raises more questions than answers.
Add to My Watchlist
What is My Watchlist?
